Ginkgo Bioworks Holdings, Inc.
(DNA)
Add Watchlist
0.81 USD +0.00
Closed: 17 May, 3:55 pm
Symbol DNA
Market Cap 1.7B
Price 0.81
Open 0.84
52-wk High 2.55
50 Day Avg 1.00
Earnings Announcement 2024-03-01
Website https://www.ginkgobioworks.com
Name Ginkgo Bioworks Holdings, Inc.
Shares Outstanding 2,211,277,945
Change % -3.9809%
Low 0.79
52-wk Low 0.72
200 Day Avg 1.44
Last Dividend 0.00
Exchange NYSE
Volume 30,724,674
Previous Close 0.84
High 0.87
EPS -0.43
PE -1.87
Avg Volume 35,987,100
CUSIP 37611X100
Ginkgo Bioworks Holdings, Inc. Outlook
Description Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Currency USD
ISIN US37611X1000
Industry Biotechnology
Changes -0.03
CUSIP 37611X100
Range 0.72 - 2.55
Beta 1.42
CIK 0001830214

Ginkgo Bioworks Holdings, Inc. News

16-May-2024 9:30 AM

4 Small-Cap Value Stocks That Could Go Parabolic

Small-cap stocks have historically responded positively to interest-rate cuts. These four small-cap equities may be poised for a bull run once the Fed eventually slashes rates.

15-May-2024 8:45 AM

What's the Difference Between Biotech Stocks and TechBio Stocks?

Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.

15-May-2024 7:01 AM

Ginkgo Bioworks to Participate in Two Conferences in May

BOSTON , May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. TD Cowen's 2nd Annual Sustainability Week: Ginkgo's Senior Director of Policy and Partnerships, Ryan Morhard, will participate in the virtual Sustainable API Manufacturing panel at 4:25 pm ET on May 22, 2024.

14-May-2024 6:00 PM

Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON , May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.

09-May-2024 10:18 PM

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2024 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2024 Earnings Conference Call May 9, 2024 5:30 PM ET Company Participants Megan LeDuc – Manager-Investor Relations Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Mike Ryskin - Bank of America Steve Mah - TD Cowen Megan LeDuc Good evening, I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.

09-May-2024 6:46 PM

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Lags Revenue Estimates

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago.

09-May-2024 4:01 PM

Ginkgo Bioworks Reports First Quarter 2024 Financial Results

Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 BOSTON , May 9, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

08-May-2024 1:46 PM

3 Meme Stocks to Sell in May Before They Crash & Burn

The stock market has been on an incredible run over the past year with tech and growth stocks surging. Traders have piled into many fast-moving companies in hopes of locking in quick trading gains.

07-May-2024 12:31 PM

Want $10,000? Invest $1,000 in These 3 Penny Stocks Now

There's the age-old adage, “You have to spend money to make money.” But then again, what if you could spend pennies and get back dollars?

07-May-2024 7:01 AM

GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener

To scale up its production of brazzein, GreenLab will leverage its proprietary technology to grow proteins inside corn kernels, optimizing its process with Ginkgo's Plant Trait Services , Protein Services , and Deployment Capabilities JONESBORO, Ark. and BOSTON , May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.

06-May-2024 7:01 AM

Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

BOSTON , May 6, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.